



Attorney Docket No. 54964.8214-1636

RECEIVED  
APR 07 2003  
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: NORDSTROM, Jeff *et al.*  
APPLICATION NO.: 09/754,014  
FILED: January 3, 2001  
FOR: **GENE EXPRESSION AND DELIVERY SYSTEMS  
AND USES**

EXAMINER: Sullivan, Daniel M.  
ART UNIT: 1636

#14

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97(c)

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. § 1.97 and 1.98, the items identified in this Information Disclosure Statement ("IDS") are brought to the attention of the Office. The items are listed on the attached form PTO-1449 and copies are enclosed for the convenience of the Examiner.

The items identified in this IDS may or may not be "material" pursuant to 37 C.F.R. § 1.56. The submission thereof by Applicant is not to be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 C.F.R. § 1.97(h)), or even qualifies as "prior art" 35 U.S.C. § 102 with respect to this invention unless specifically designated by Applicant as such.

This IDS is being filed after an action on the merits but before a Final Action under 37 C.F.R. § 1.113 or a Notice of Allowance under 37 C.F.R. § 1.311. Enclosed is a check of \$ 180.00 to cover the fee pursuant to 37 C.F.R. § 1.17(p). In the event that this IDS is not received before a Final Action under 37 C.F.R. § 1.113 or a Notice of Allowance under 37 C.F.R. § 1.311, then the Applicant respectfully requests that the Office consider the filing of these papers to be a petition


[54964-8214/LA030840.064]

under 37.C.F.R. § 1.97(d). The Commissioner is hereby authorized to charge any additional fees required by this paper to the Deposit Account No. **50-0665**, please credit any overpayments to the same.

Respectfully submitted,

Perkins Coie LLP

Dated: 3/26/03

By:   
James J. Zhu, Ph.D.  
Reg. No. 52,396

Correspondence Address:



Perkins Coie LLP  
Patent – LA  
P.O. Box 1208  
Seattle, WA 98111-1208  
Phone: (310) 788-9900  
Fax: (310) 788-3399

54964.8214.US04

09/754,014

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S  
INFORMATION DISCLOSURE STATEMENT

## APPLICANT:

Nordstrom, Jeff et al

## EXAMINER:

Sullivan, Daniel M

## FILING DATE:

January 3, 2001

## GROUP:

1636

(Use several sheets if necessary)

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

AZ	Chapman et al., "Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells", Nucleic Acids Research 19: 3979-3986 (1991).
CE	Smith, Herbert A., "Regulatory considerations for nucleic acid vaccines", Vaccines 12: 15151519 (1994).
CG	Tahara et al., "Effective Eradication of Established Murine Tumors with IL-12 Gene Therapy Using a Polycistronic Retroviral Vector", The American Association of Immunologists 6466-6474 (1995).
CO	Freimark et al., "Cationic Lipids Enhance Cytokine and Cell Influx Levels in the Lung Following Administration of Plasmid: Cationic Lipid Complexes", The American Association of Immunologies 4580-4586 (1998).
CP	Liang et al., "Novel, high expressing and antibiotic-controlled plasmid vectors designed for use in gene therapy", Gene Therapy 3: 350-356 (1996).
CU	Haas et al., "Codon usage limitation in the expression of HIV-1 envelope glycoprotein", Current Biology 6: 315-324 (1996).
CV	Zolotukhin et al., "A 'Humanized' Green Fluorescent Protein cDNA Adapted for High-Level Expression in Mammalian Cells", Journal of Virology 70: 4646-4654 (1996).
CW	Bramson et al., "Construction of a Double Recombinant Adenovirus Vector Expressing a Heterodimeric Cytokine: <i>In Vitro</i> and <i>In Vivo</i> Production of Biologically Active Interleukin-12", Human Gene Therapy 7: 333-342 (1996).
CX	Gubler et al., "Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor", Proc. Natl. Acad. Sci. 88: 4143-4147 (1991).
CY	Meko et al., "Cytokine production and antitumor effect of a nonreplacing, noncytopathic recombinant vaccinia virus expressing interleukin-12", Surgery 120: 274-283 (1996).
CZ	Mount, "AT-AC Introns: An ATtACK on Dogma", Science 271: 1690-1692 (1996).

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant